Atommap Corporation
- | Biotech or pharma, therapeutic R&D
- | Other R&D services
Atommap is transforming drug discovery through cutting-edge computational tools. Our proprietary platform integrates physics-based modeling and machine learning to accelerate the design of novel therapeutics. Since securing seed funding from Sutter Hill Ventures in November 2023, we have successfully identified and advanced first-in-class, mutant-selective molecules targeting a well-validated oncogenic driver.
Our platform not only drives our internal pipeline but also accelerates discovery programs for our partners. What distinguishes Atommap is our ability to generate new therapeutic hypotheses for previously undruggable targets, apply hypothesis-driven generative chemistry for molecule design, and predict functional outcomes with high precision—enabling smarter, faster candidate selection.
Our vision is to become the premier partner for end-to-end drug discovery, delivering clinical candidates with unprecedented speed across a broad range of disease targets.
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}